Compare OSS & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OSS | GALT |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 197.3M | 199.2M |
| IPO Year | 2017 | 2008 |
| Metric | OSS | GALT |
|---|---|---|
| Price | $9.10 | $2.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $10.00 | $8.50 |
| AVG Volume (30 Days) | ★ 1.5M | 349.4K |
| Earning Date | 03-18-2026 | 03-31-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | N/A |
| EPS | ★ 0.22 | N/A |
| Revenue | ★ $37,027,382.00 | N/A |
| Revenue This Year | $13.57 | N/A |
| Revenue Next Year | $23.40 | N/A |
| P/E Ratio | $40.23 | ★ N/A |
| Revenue Growth | ★ 34.46 | N/A |
| 52 Week Low | $1.85 | $1.15 |
| 52 Week High | $12.75 | $7.13 |
| Indicator | OSS | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 43.60 |
| Support Level | $7.95 | $2.57 |
| Resistance Level | $10.74 | $3.32 |
| Average True Range (ATR) | 0.96 | 0.23 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 22.80 | 25.00 |
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy. The company operates in two reportable segments; OSS designs and manufactures high-performance customized computers and flash arrays, in-flight entertainment & connectivity. Bressner operates as a system integrator with standard and custom all-in-one hardware systems and components for many kinds of industrial environments. The company generates the majority of its revenue from the Bressner segment.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.